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Approximately 775,000 hip and knee arthroplasties are performed yearly in the United States, with a dramatic increase expected.
Patients having hip and knee arthroplasties are at high risk of developing a venous thromboembolism. The American College of
Chest Physicians (ACCP) and the American Academy of Orthopedic Surgeons (AAOS) have updated guidelines, which outline
new prophylactic strategies. Factor Xa inhibitor rivaroxaban has a new recommendation by ACCP and is gradually being adopted
by the joint arthroplasty community as an eﬀective oral agent. Other more well-known agents including warfarin, low-molecular-
weight heparin, aspirin, and fondaparinux continue to be options for prophylaxis. While the goal of prophylaxis continues to be
the prevention of venous thromboemboli and pulmonary emboli, it is important to consider the increased bleeding risk associated
with their use. The most recent ACCP and AAOS guidelines give clinicians a greater autonomy in choosing a prophylactic agent
with greater emphasis placed on dialogue between the surgeon and patient as to the choice of prophylaxis.
1.Introduction
Approximately 775,000 hip and knee arthroplasties are
currently performed yearly in the United States [1]. With
the population of adults over 65 years of age in the United
States projected to double from 35 million in 2000 to 72
million in 2030 [2], a dramatic increase in the number
of total joint arthroplasties (TJAs) will likely be seen.
Patients undergoing lower extremity surgery, especially TJA
procedures,areinherentlyathighriskofdevelopingavenous
thromboembolism (VTE). Historically, it has been reported
that up to 40–60% of patients undergoing total hip (THA)
and total knee arthroplasty (TKA) in the absence of throm-
boprophylaxis will develop either venographic evidence of a
deep venous thrombosis (DVT) or a pulmonary embolism
(PE) postoperatively [3]. Currently with modern techniques
and postoperative care, the estimated risk of developing a
symptomatic VTE without prophylaxis is around 4.3% [4].
To address the high patient morbidity and mortality due
to VTE, thromboprophylaxis is routinely applied to TJA.
Multiple agents, including low-molecular-weight heparin,
aspirin, warfarin, fondaparinux, rivaroxaban, and mechani-
cal prophylaxis, have contributed to a reduction in frequency
of VTE, although the risk of symptomatic VTE remains
a p p r o x i m a t e l y2 %w i t h i n3 5d a y sa f t e rm a j o ro r t h o p e d i c
surgery [4]. Interestingly, fatal PE has remained consistent
in primary THA and TKA, between 0.1 and 2%, no matter
which agents are used [5, 6].
Both the American College of Chest Physicians (ACCP)
and the American Academy of Orthopedic Surgeons (AAOS)
have recognized the risk reduction from antithrombotic
agents, but there is still controversy as to which agent(s)
has the most eﬃcacy, the appropriate timing of dosing,
and the duration of prophylaxis. A delicate balance exists
between VTE prophylaxis and systemic and surgical site
bleeding, which can lead to surgical wound complications
including infection, hematoma, reoperation, and systemic
bleeding (gastrointestinal). A large meta-analysis performed
by Muntz et al. [7] compared the relative risks of bleeding
among the major prophylactic agents (warfarin, heparin,
low molecular weight heparin, and pentasaccharides) and
determined the extra cost to treat complications associated
with bleeds, including reoperation, was $113 per patient
receiving prophylaxis; thus, fostering a debate between
surgical and medical practitioners as to the risk beneﬁt ratios
of diﬀerent treatment modalities. The purpose of this review2 Thrombosis
is to discuss the eﬃcacy of the most commonly used VTE
agents and provide clinicians with treatment options for
discussion with their patients.
2. Pathogenesis
Rudolph Virchow proposed that 3 etiologic factors give
rise to thrombosis: vascular endothelial damage, stasis of
blood ﬂow, and hypercoagulability of blood [8]. Risk for
VTE increases as predisposing factors increase (Box 1).
TJA exposes a patient to each portion of the triad during
the operative period. Endothelial damage may occur with
retractor placement, dislocation procedures, thermal injury
during cement hardening, placement of the prostheses, and
lower extremity manipulation during the surgery. Stasis may
occurfrompositioningduringtheoperativeprocedure,from
perioperative swelling, occlusive dressings, and decreased
mobility [6]. A hypercoagulable state may occur as a result of
blood loss, loss of anticlotting factors, and potentially from
lipids and collagen release during the surgical procedure.
Previously published guidelines have advocated for risk
stratiﬁcation of patient factors, but no consensus has been
reached as to how to do so or if this stratiﬁcation is actually
of clinical beneﬁt. Some risk factors for VTE include prior
VTE, advanced age (>40 years), obesity, cancer history, bed
rest >5 days, congestive heart failure, varicose veins, estrogen
treatment, stroke, multiple trauma, childbirth, myocardial
infarction, and hypercoagulable states such as protein C or S
deﬁciency, antithrombin III deﬁciency, lupus anticoagulant,
antiphospholipid antibodies, and myeloproliferative disor-
ders.
3.ACCPGuidelines
The ACCP ﬁrst published VTE prophylaxis guidelines in
1986 and have subsequently updated their guidelines with
the advent of new pharmacologic agents, improved surgi-
cal technique, and newer publications. The current 2012
guidelines discuss the “use of prophylaxis to reduce the
patient-important outcomes of fatal and symptomatic PE
and symptomatic DVT balanced against the hazard of an
increase in symptomatic bleeding events.” [4] Recommenda-
tions were based on a grading scale of published evidence-
based medicine criteria. Grade I indicated strong evidence
where beneﬁts did or did not outweigh risk, burden, and
cost. Grade II indicated less empirical consensus. Further
stratiﬁcation within each grade included (A) randomized
controlledtrials,unbiased,consistentresults(B)randomized
controlled trials with inconsistent results or design ﬂaw, and
(C) observational studies. The guidelines are meant as a
“guide” to help clinicians sort through the myriad of data for
appropriate patient treatments.
The current guidelines (9th edition) for patients under-
going elective THA or TKA include Grade IB evidence for
prophylaxis with low-molecular-weight heparin (LMWH),
fondaparinux, apixaban, dabigatran, rivaroxaban, low-dose
unfractionated heparin (LDUH), adjusted dose vitamin
K antagonists (VKA), and aspirin. Speciﬁc dosing is not
recommended although many of the cited studies do provide
speciﬁc dosing. There is a Grade 1C recommendation for
use of intermittent pneumatic compression devices (IPCDs).
These agents are recommended for a minimum of 10–
14 days. A Grade 1B recommendation was made to start
LMWH >12 hours preoperatively or postoperatively. This
followed a systematic review that showed dosing within 12
hours of surgery caused an increase in bleeding. A Grade 2B
recommendation was given in favor of LMWH relative to the
other agents except VKA or aspirin, which carried Grade 2C.
This was in spite of the use of IPCD or treatment duration.
There is also a Grade 2B recommendation to extend any
VTE treatment up to 35 days from the procedure rather than
10–14 days. Grade 2C evidence suggests dual prophylaxis
with IPCDs and a pharmacologic agent while in the hospital,
use of IPCDs or no prophylaxis if there is an increased
bleeding risk, use of an oral agent other than aspirin if a
patient is unwilling to administer injections or use an IPCD,
a n da g a i n s tt h eu s eo fI V Cﬁ l t e r sf o rp r i m a r yp r e v e n t i o n
over no prophylaxis in patients with an increased bleeding
risk or contraindication to other prophylaxis. Finally, Grade
1B evidence recommends against screening asymptomatic
patients before hospital discharge.
These guidelines diﬀered signiﬁcantly from previous
guidelines. First, several other agents are now mentioned
in the recommendations such as aspirin (previously rec-
ommended against as a sole agent), dabigatran, apixaban,
rivaroxaban, and LDUH (previously recommended against
as a sole agent). Second, no speciﬁc dosages are recom-
mended (although some are inferred based on cited studies).
Third, 2012 recommendations are given for both THA and
TKA, not separately as in 2008.
4. AAOS Guidelines
T h eA A O Sg u i d e l i n e s[ 9] consisted of graded levels of
evidencefromwhichtheauthorsprovidedaﬁnalrecommen-
dation.Thesewerestrong(good-qualityevidence),moderate
(fair-quality evidence), weak (poor-quality evidence), incon-
clusive (insuﬃcient or conﬂicting evidence), or consensus
(in the absence of reliable evidence, the workgroup made
recommendations based on clinical judgment).
The set of ten recommendations were as follows: (1)
recommendation against postoperative ultrasound screening
(strong); (2) determination whether patient had a previous
VTE (weak), unable to recommend for or against assessing
patients for VTE risk factors (inconclusive); (3) patients
should be assessed for bleeding disorders such as hemophilia
oractiveliverdisease(consensus),andunabletorecommend
for or against using other risk factors to assess bleeding risk
(inconclusive); (4) patients should discontinue the use of
antiplatelet agents before undergoing elective hip or knee
arthroplasty (moderate); (5) the academy suggests the use
of pharmacologic and/or mechanical prophylaxis in patients
who are not at elevated risk for VTE or bleeding beyond
that of the surgery itself (moderate), is unable to recommend
for or against speciﬁc prophylactic strategies (inconclusive),
and in the absence of reliable evidence as to the length
of prophylaxis, physicians should discuss the length of
prophylaxis with their patients (consensus); (6) the academyThrombosis 3
Surgery
Trauma (major trauma or lower-extremity injury)
Immobility, lower-extremity paresis
Cancer (active or occult)
Cancer therapy (hormonal, chemotherapy, angiogenesis inhibitors, radiotherapy)
Venous compression (tumor, hematoma, arterial abnormality)
Previous VTE
Increasing age
Pregnancy and the postpartum period
Estrogen-containing oral contraceptives or hormone replacement therapy
Selective estrogen receptor modulators
Erythropoiesis-stimulating agents
Acute medical illness
Inﬂammatory bowel disease
Nephrotic syndrome
Myeloproliferative disorders
Paroxysmal nocturnal hemoglobinuria
Obesity
Central venous catheterization
Inherited or acquired thrombophilia
Box 1: Risk factors for venous thromboembolism from the American College of Chest Physicians.
recommends that patients with known bleeding disorders or
active liver disease use mechanical prophylaxis (consensus);
(7) the academy suggests that patients with previous VTE
receive pharmacologic and mechanical prophylaxis (consen-
sus); (8) the academy recommends patients should undergo
early mobilization (consensus); (9) the academy suggests the
use of neuraxial anesthesia to limit blood loss even though
i t sd o e sn o ta ﬀect occurrence of VTE (moderate); (10) the
academy is unable to recommend for or against IVC ﬁlters
(inconclusive).
5. Treatment Options
5.1. Aspirin. Aspirin (acetylsalicylic acid, ASA) irreversibly
blocks cyclooxygenase and the formation of thromboxane
A2, a potent platelet aggregator. This results in disabling
the clotting ability of platelets (Figure 2). ASA is a very
attractive treatment option for many surgeons because of
its ease of administration, low expense, decreased risk for
bleeding complications, and lack of monitoring. Several
studies have shown an added beneﬁt by decreasing the risk
of heterotopic ossiﬁcation [10, 11]. Previous recent studies
advocated dosages in a wide range but currently low-dose
aspirin (75mg–325mg) has been advocated.
The use of aspirin as a VTE prophylactic modality has
been a topic of debate for many years. The ACCP has
previously advocated against its use alone as a chemopro-
phylactic agent because several studies have shown other
agents to be more eﬃcacious. The ACCP discounted the
Antiplatelet Trialist Collaboration [12], which showed that
ASA has beneﬁt in protecting against DVT and an even
greater beneﬁt in protecting against PE. The ACCP stated
that this meta-analysis had a pool of poor quality data, and
the DVT detection methods were substandard. They also
stated that a number of trials showed no signiﬁcant beneﬁt
and/or inferior results compared to other prophylactic
agents. Recently, Woller et al. [13] prospectively studied 696
patients having either TKA or THA and classiﬁed 281 as
AAOS standard risk or elevated risk (2008 guidelines). The
other 415 patients received ACCP-recommended treatment
with warfarin or enoxaparin. The standard risk patients
receiving ASA had a signiﬁcantly higher rate of symptomatic
PE (4.6% versus 0.7%, P<. 030) and VTE (7.9% versus
1.2%, P<. 001) than the patients receiving warfarin.
However, in their most current guidelines, the ACCP has
given ASA a grade 1B recommendation of support. Current
ACCP recommendations state that ASA has a modest risk
reduction in symptomatic DVT and that taking low-dose
ASA for 35 days will result in seven fewer symptomatic
VTEs per 1000 patients. They do caution that ASA may also
result in more major nonfatal bleeding episodes compared to
placebo (RR 1.12), but there was no diﬀerence in bleeding
requiring reoperation or bleeding death. There was also
a trend toward nonfatal myocardial infarctions compared
to placebo (RR 1.59), which resulted in 2 more nonfatal
myocardial infarctions per 1000 patients [4].
The AAOS, on the other hand, has advocated for
the use of ASA for patients with a standard risk (no
history of malignancy, no previous clots, no history of
thrombophilia) of PE. Their previous guidelines pointed out
simply that if a patient developed a DVT, he or she would
not inherently develop a symptomatic DVT or PE. Bozic
et al. [14] retrospectively analyzed over 93,000 patients in
the United States having primary TKA between October
2003 and September 2005 and found that those patients
who received ASA had lower adjusted odds radio for VTE
and PE compared to warfarin (OR 1.36, P<. 01) and
similar adjusted odds ratio compared to injectable agents
(OR 1.03, P<. 01). Similarly, in a retrospective analysis
of the total joint registry, Khatod et al. [15] showed that
treatmentwithASAinTHAhadnodiﬀerenceinthePE,fatal4 Thrombosis
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Figure 1: Coagulation Cascade.
PE, or death compared with other prophylactic measures.
Lotke et al. [16] also demonstrated that ASA, combined with
other AAOS recommended measures and improved surgical
techniques, is safer than and equally eﬃcacious as other
chemoprophylaxis agents at preventing fatal PE .06%–0.14%
( e x p e c t e dp r e v a l e n c ei nl i t e r a t u r e0 . 1 % ) ,n o n f a t a lP E0 . 2 6 %
(expected prevalence in literature <1%), and symptomatic
DVT 0.2% (expected prevalence <3%). Currently the 2011
AAOS does not recommend for or against the use of aspirin
but simply states that a chemoprophylactic agent should be
used.
5.2. Rivaroxaban. Rivaroxaban is an oral, once a day,
reversible, direct factor Xa inhibitor (Figure 1). It requires
no monitoring and has recently been approved for use in
the United States for the prophylaxis of VTE in primary
THA and TKA. This drug was studied in the RECORD
trials (1–4), which evaluated the drug’s eﬃcacy against
enoxaparin [17]. Almost 13,000 patients were evaluated for
primary endpoints of symptomatic DVT, non-fatal PE, and
all-cause mortality in both THA (RECORD 1 and 2) and
TKA (RECORD 3 and 4) at the end of the medication
period. RECORD 1 compared rivaroxaban 10mg qday for
5 weeks versus 40mg enoxaparin qday for 5 weeks, and
RECORD 2 compared rivaroxaban 10mg qday for 5 weeks
versus 40mg enoxaparin for 10–14 days plus oral placebo.
RECORD 3 compared rivaroxaban 10mg qday for 10–14
days versus enoxaparin 40mg qday for 10–14 days, and
RECORD 4 compared rivaroxaban 10mg qday for 10–14
days versus enoxaparin 30mg BID for 10–14 days. The pri-
mary safety endpoints were major bleeding which included
surgical site bleeding that required reoperation, major and
clinically relevant nonmajor bleeding, and any bleeding.
A pooled analysis of these studies showed that rivaroxaban
had superiority over enoxaparin in preventing major venous
thromboembolism deﬁned as a composite of proximal deep
vein thrombosis, nonfatal pulmonary embolism, or death
fromvenousthromboembolism[RECORD1–3(0.5%versus
1.3% P<. 001)] and RECORD 4 (6.9% versus 10.1% P<
.0118)]. With regards to safety endpoints, there was no
statistical signiﬁcance between enoxaparin and rivaroxaban
inanyRECORDstudies.Inasimilarpositiveanalysis,Kwong
[18] showed that rivaroxaban was a cost-eﬀective alternative
to enoxaparin.
Most surgeons are concerned about the potential for
surgical site bleeding and hematoma formation. These
complications may lead to drainage, infection, and return to
the operative suite. This is associated with patient morbidity
and a signiﬁcant cost burden. In a retrospective cohort study,
Jensen et al. [19] evaluated this issue in 1048 patients having
THA and TKA. One group of 489 patients received tinza-
parin 4500u qday, and one group of 536 patients received
rivaroxaban10mgqday.Intheﬁrst30dayspost-op,9(1.8%)
patients in the tinzaparin group returned to the operative
suiteforopenirrigationanddebridementforeitherinfection
or hematoma, compared to 22 (3.94%) patients in the
rivaroxaban group. This increase was statistically signiﬁcant,
P = .046.
While rivaroxaban has shown prophylactic eﬃcacy in
both THA and TKA, it must be used with caution as it may
cause an increase in surgical site complications. Its ease of
use as an oral agent that requires no monitoring may also be
advantageous in noncompliant patients.
5.3. Warfarin. Discovered in 1921 and used as a roden-
ticide since the 1940s, warfarin has been used as lowThrombosis 5
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Figure 2: COX pathway.
cost anticoagulant since the 1950s. Warfarin impairs the
creation of the clotting factors II (prothrombin), VII, IX,
and X by inhibiting vitamin K epoxide reductase (Figure 1).
Multiple meta-analyses and trials have compared warfarin to
LMWH, ASA, LDUH, and mechanical prophylaxis and have
showed its eﬃcacy. With compliance of INR 2-3, warfarin
appears similar in VTE prevention and has lower rates of
bleeding complications compared to LMWH and LDUH
[13, 20, 21].
Unfortunately, it may be diﬃcult to control the thera-
peutic window of warfarin. In a retrospective cohort design,
Nordstrom et al. [22]e v a l u a t e dI N Rp a t t e r n si nac o h o r t
of patients who had received a TKA/THA relative to VTE
prevalence. They found that the majority (∼83%) of THA
and TKA patients were not therapeutic (INR 2-3) on post-op
day 4 of their surgery, a time of increased VTE risk. Over the
duration of their warfarin treatment (32–35 days), roughly
one-third of the INR levels (33.3% THA and 28.6% TKA)
fell within the 2008 ACCP-recommended INR range of 2.0–
3.0. Moreover, in both cohorts of patients, VTE was strongly
dependent on the INR with a 4-5-fold increased risk for VTE
in patients who did not achieve an INR >2.0.
Drug interactions and bleeding risks with warfarin are
of concern. Warfarin is metabolized by the cytochrome
P450 enzymes and has a long list of drug interac-
tions, some of which enhance (e.g., quinolones, trimetho-
prim/sulfamethoxazole, and antifungals) and that dimin-
ish (e.g., phenytoin, carbamazapine, phenobarbital, and
rifampin) the eﬃcacy of its anticoagulation. This property
makes dosing and maintaining a consistent INR value very
diﬃcult.Delayedonsetofactionalsomaymakemanagement
diﬃcultly, leading many physicians to bridge this “gap” of
sub-therapeutic INR with another chemoprophylaxis (e.g.,
UFH or LMWH). Large loading doses, elderly persons >75,
liver disease, and drug interactions are all risk factors for
increasing INR and increasing bleeding. Although warfarin
has excellent eﬃcacy within its therapeutic window, diﬃcul-
ties remain dealing with early and late INR variations as well
as the albatross of chronic monitoring.
5.4. LMWH. LMWHs bind to and accelerate the activity of
antithrombin III, potentiating the inhibition of coagulation
factor Xa and thrombin (Figure 1). LMWH has more con-
trolled binding properties to plasma proteins than unfrac-
tionatedheparin,deliveringamoreconsistentdoseresponse,
better bioavailability, and less potential to cause heparin-
induced thrombocytopenia (HIT) [23]. The combination of
its consistent bioavailability, linear pharmacokinetics, and
short half-life make it a very attractive option for the
prevention of VTE.
Many trials have compared the eﬃcacy of LMWH to
warfarin and UFH in the prevention of DVT and PE
following joint arthroplasty. Many prospective, randomized,
and sometimes multi-institutional trials have found LMWH
tobesuperiortoUFHandwarfarininthepreventionofDVT
[24–26]. Fitzgerald et al. [25]pe rf o rm e dara n d o m i z e d ,m u l -
ticenter trial of 349 patients comparing enoxaparin (30mg
SC BID) to warfarin (INR 2-3) and found an estimated odds
ratio for the development of VTE to be 2.52 times greater
with warfarin than enoxaparin. Although not statistically
signiﬁcant, the episodes of major and minor hemorrhagic
episodes in the warfarin treated patients (23%, 41 of 176)
were lower than that of the enoxaparin treated group (34%,
58 of 173). In a prospective randomized trial, Warkentin et
al. [23] had similar results with a signiﬁcantly lower rate
of DVT in the LMWH group compared to warfarin (15%
compared to 26%, P = .006). Blood loss and decreased
hematocrit between the two groups were similar; however,
the LMWH group required more blood transfusions in the
1st through 8th postoperative day and, as mentioned in the
aforementioned pro-warfarin studies, had more operative
site bleeding complications.
Postoperative complications following early prophylaxis
with LMWH are well outlined in the literature and include
wound necrosis, sciatic nerve palsy secondary to postoper-
ative hematoma, drainage, and persistent hematoma at the
surgical site. Due to its rapid onset of action, it should not
be initiated for 12 hours after neuraxial anesthesia in order
to prevent epidural hematoma and neurologic deﬁcits, and6 Thrombosis
it is contraindicated in individuals with indwelling spinal
catheters. LMWH should not be administered for at least
4 hours after an epidural catheter has been removed. All
of these factors play a crucial role in balancing the beneﬁts
of DVT/PE prevention versus the deleterious complications
associated with bleeding.
5.5. Fondaparinux. Fondaparinux is a synthetic oligosaccha-
ride that is based on the pentasaccharide sequence of the
heparin and LMWH molecules that is responsible for its
binding aﬃnity to antithrombin III (Figure 1). This selective
aﬃnity allows for less interaction with plasma proteins and
other molecules in the clotting cascade. Fondaparinux has
been proven safe in the treatment of patients with HIT,
demonstrating no HIT-like reaction in these patients’ serum
samples. Being almost exclusively excreted by the kidneys,
it must be used judiciously for patients with renal disease
having a creatinine clearance <50mL/min [27, 28], and it is
contraindicated in patients with CrCl <30.
The majority of fondaparinux trials for prevention of
VTE after arthroplasty have been in direct comparison to
LMWH due to their similarity. A meta-analysis of 4 ran-
domized double-blinded studies found that fondaparinux
(2.5mg SC daily) administered 6 hours after major ortho-
pedic surgery signiﬁcantly reduced the incidence of VTE
by day 11 [182 (6.8%) of 2682] compared with enoxaparin
administered either 40mg SC daily or 30mg SC twice daily
[371 (13.7%) of 2703], P<. 01 [29]. While the rate of
VTE was lower, there was no diﬀerence in the reduction of
fatal PE, and importantly there was a statistically signiﬁcant
increase in major bleeding episodes in the fondaparinux
group [96 (2.7%) of 3616] compared to the enoxaparin
group [63 (1.7%) of 3621], P = .008. However, there was
no diﬀerence in the incidence of clinically relevant bleeding
between the two groups leading to death or reoperation.
Bauer et al. [30] conﬁrmed these data with a prospective,
randomized,double-blindstudyof1049patientsundergoing
electiveTKA.Theyfoundastatisticallysigniﬁcantdecreasein
VTE by day 11 in the fondaparinux compared to enoxaparin
(12.5% to 27.8%) with a risk reduction of 55.2% (P<. 001).
Similarly, major bleeding episodes occurred more frequently
in the fondaparinux group. Turpie et al. [28] examined
the relationship of bleeding and the timing of the ﬁrst
dose of fondaparinux in patients undergoing elective major
hip and knee surgery, or standard surgery for the fracture
of the proximal third of the femur. When fondaparinux
was given 3–6 hours of surgery, the incidence of major
bleeding was higher (3.2%, 42/1300) than when it was given
within 6–9 hours of surgery (2.1%, 46/2171, P<. 045);
although when factoring out major bleeds that occurred
before administration of the ﬁrst dose of fondaparinux
(15/88), the diﬀerence between the 2 groups does not reach
statistical signiﬁcance, P<0.18. Thus, there is still a
debate about the timing of the ﬁrst postoperative dose of
fondaparinux with most clinicians recommending at least 6–
8 hours postoperatively before administration.
Fondaparinux appears to have excellent eﬃcacy in the
prevention of VTE following major orthopedic surgery but
shows no superiority in the prevention of fatal PE. However,
it carries a signiﬁcantly higher risk of major bleeding
episodes compared to LMWH. Clinical judgment must be
used in patients with renal impairment, which is common
in elderly patients undergoing TJA, and patients weighing
<50kg. Therefore, while eﬀective, this medication should be
used with caution if bleeding is of concern.
6. Discussion
ThenewerAAOSandACCPguidelinesseemtobeapproach-
ing the center with their views on prophylaxis. The previous
2008 ACCP guidelines were more speciﬁc with what they
deemed necessary for full prophylaxis against DVT, gave
dosages, INR ranges, and timelines within which to start
and stop prophylaxis. They also did not appear to appreciate
operative site bleeding as much as many surgeons would
like to. The new guidelines are more accepting of varied
pharmacologic prophylaxis and deﬁnitions of adequacy.
The current guidelines recommend aspirin as a choice for
prophylaxis and are accepting of some new factor Xa and
thrombin inhibitors. In addition, they have shifted focus
away from asymptomatic DVT and other clinically irrelevant
end points to the more relevant symptomatic DVT and PE.
This is a change that has been advocated by the AAOS.
The AAOS has also shifted its focus from past years’
guidelines. Unlike previous years, the 2011 guidelines were
unable to conclude on any speciﬁc prophylactic strategies
and were also unable to make recommendation regarding
the length of postoperative prophylaxis. They allow the
surgeon more autonomy based on clinical judgment for the
prevention of postoperative VTE. The AAOS encourages
active discussion between patient and surgeon regarding the
risks and beneﬁts of the speciﬁc treatment agents as well
as the length of postoperative prophylaxis. Some surgeons
may disagree with this strategy for medical, legal or other
reasons and may desire more standardized care. However,
the goal appears to be engagement of the patient in the
clinical decision-making and a focus on individualized care
recommendations.
7. Conclusions
More prophylactic options exist now than with previous
guidelines. New to treatment guidelines are apixaban, dabi-
gatran, and rivaroxaban, all of which are recommended by
the ACCP for prophylaxis (only rivaroxaban is approved for
use in the United States). These agents seem to have excellent
eﬃcacy in preventing VTE but may increase operative site
bleeding. Fondaparinux is also a very eﬃcacious choice but
operative site bleeding seems to continue to be a concern.
Enoxaparin has remained a stalwart in the treatment of VTE
and may now be seen as the gold standard for this class of
agent, keeping bleeding complications relatively low while
remaining very eﬃcacious. The new guidelines have put
aspirin in a new light. A shift from previous practice has
placedaspirinonparwithotherprophylacticstrategies.War-
farin remains a steady choice for many orthopedic surgeons.
Its eﬃcacy cannot be questioned, but the bleeding risk and
the cumbersome monitoring make its use problematic.Thrombosis 7
Many prophylactic choices are available to orthopedic
surgeons, all of which have demonstrated eﬃcacy. Unfor-
tunately with this eﬃcacy comes the constant concern
of bleeding risks. New guidelines give surgeons increased
freedom to decide which agent provides their patients an
acceptable bleeding risk and reduction in VTE risk. This
dialogue will become an integral part of the surgeon-patient
relationshipasmoreandmorepeoplehavejointreplacement
surgery.
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